Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT01088243

Targeting Oxidative Stress in Chronic Beryllium Disease

Sponsor: National Jewish Health

Updated 7 times since 2017 Last updated: Sep 12, 2018 Started: Mar 31, 2010 Primary completion: Mar 31, 2015 Completion: Mar 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01088243, this PHASE1/PHASE2 trial focuses on Chronic Beryllium Disease and remains completed. Sponsored by National Jewish Health, it has been updated 7 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Nov 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Nov 2018 [monthly]

Completed PHASE1_PHASE2

▶ Show 2 earlier versions

Dec 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Dec 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Mar 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Jewish Health

Data source: National Jewish Health

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Denver, United States